JAZZ
Jazz Pharmaceuticals plc
Price Chart
Latest Quote
$226.20
-3.65 (-1.59%)
Current Price
| Previous Close | $229.85 |
| Open | $230.02 |
| Day High | $233.00 |
| Day Low | $224.95 |
| Volume | 673,082 |
Stock Information
| Shares Outstanding | 62.82M |
| Total Debt | $5.42B |
| Cash Equivalents | $2.87B |
| Revenue | $4.44B |
| Net Income | $29.45M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $14.21B |
| P/E Ratio | 2056.36 |
| EPS (TTM) | $0.11 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $16.74B |
| Sales | $4.44B |
| Income | $29.45M |
| Book/sh | $72.28 |
| Cash/sh | $45.76 |
| Employees | 3K |
Financial Ratios
| Quick Ratio | 1.65 |
| Current Ratio | 2.04 |
| Debt/Eq | 119.52 |
Returns & Margins
| ROA | 6.92% |
| ROE | 0.68% |
| Gross Margin | 91.50% |
| Operating Margin | 23.51% |
| Profit Margin | 0.66% |
Ownership
| Insider Ownership | 3.12% |
| Institutional Ownership | 108.17% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 8.83 |
| PEG | 0.96 |
| P/S | 3.20 |
| P/B | 3.13 |
Analyst Data
| Recommendation | buy |
| Target Price | $257.00 |
Technical Indicators
| SMA20 | $230.95 |
| SMA50 | $222.73 |
| SMA200 | $177.01 |
| RSI | 32.30 |
| ATR | 6.7636 |
| Shares Float | 60.81M |
| Short Float | 7.04% |
| Short Ratio | 4.67 |
| Volatility | 0.33 |
| Rel Volume | 0.69 |
Performance History
| Week | -0.32% |
| Month | -4.72% |
| Quarter | +19.63% |
| 6 Months | +33.32% |
| YTD | +30.64% |
| Year | +109.23% |
| 3 Years | +76.65% |
| 5 Years | +27.26% |
| 10 Years | +70.58% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $226.20 | 673,082 |
| 2026-06-24 | $229.85 | 719,900 |
| 2026-06-23 | $230.25 | 862,800 |
| 2026-06-22 | $225.92 | 980,000 |
| 2026-06-18 | $224.66 | 1,906,800 |
| 2026-06-17 | $226.93 | 680,000 |
| 2026-06-16 | $226.88 | 770,200 |
| 2026-06-15 | $230.59 | 691,000 |
| 2026-06-12 | $230.56 | 635,700 |
| 2026-06-11 | $236.17 | 954,400 |
| 2026-06-10 | $229.63 | 954,800 |
| 2026-06-09 | $229.19 | 727,800 |
| 2026-06-08 | $232.04 | 1,208,500 |
| 2026-06-05 | $238.57 | 678,000 |
| 2026-06-04 | $240.06 | 1,296,600 |
| 2026-06-03 | $230.93 | 910,500 |
| 2026-06-02 | $226.12 | 1,364,700 |
| 2026-06-01 | $232.64 | 945,700 |
| 2026-05-29 | $236.49 | 1,766,200 |
| 2026-05-28 | $235.38 | 667,700 |
| 2026-05-27 | $237.56 | 615,300 |
| 2026-05-26 | $237.41 | 660,100 |
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
đ° Latest News
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?
Zacks âĸ 2026-06-25T12:45:00Z
Jazz Pharmaceuticals (JAZZ) Stock Gets Fair Value Boost As Ziihera Views Split Analysts
Simply Wall St. âĸ 2026-06-24T19:14:33Z
Jazz Pharmaceuticals (JAZZ) Expands AbCellera Tie Up As Zepzelca Trial Misses Goal
Simply Wall St. âĸ 2026-06-24T08:09:02Z
Jazz Pharmaceuticals and AbCellera Biologics Inc. (ABCL) Announce Collaboration
Insider Monkey âĸ 2026-06-23T19:39:56Z
Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks
Motley Fool âĸ 2026-06-23T19:00:00Z
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies
Zacks âĸ 2026-06-18T14:29:00Z
Jazz and AbCellera sign deal for T-cell engagers in solid tumours
Pharmaceutical Technology âĸ 2026-06-18T10:33:13Z
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Fed Rates Announcement
MT Newswires âĸ 2026-06-17T13:15:53ZJazz Pharmaceuticals and AbCellera Partner on Antibody Programs for Solid Tumors
InvestorsHub âĸ 2026-06-17T12:50:06Z
Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?
StockStory âĸ 2026-06-15T21:48:07Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $461,660,000 | $412,959,000 | $405,165,000 | $510,215,000 |
| Cost Of Revenue | $503,296,000 | $445,713,000 | $435,577,000 | $540,517,000 |
| Total Revenue | $4,267,586,000 | $4,068,950,000 | $3,834,204,000 | $3,659,374,000 |
| Operating Revenue | $4,267,586,000 | $4,068,950,000 | $3,834,204,000 | $3,659,374,000 |
| Expenses | ||||
| Interest Expense | $195,051,000 | $238,097,000 | $289,438,000 | $288,242,000 |
| Total Expenses | $3,749,964,000 | $3,342,320,000 | $3,236,624,000 | $3,147,106,000 |
| Other Income Expense | $-950,430,000 | $-18,182,000 | $-10,213,000 | $-596,810,000 |
| Net Non Operating Interest Income Expense | $-195,051,000 | $-238,097,000 | $-289,438,000 | $-288,242,000 |
| Interest Expense Non Operating | $195,051,000 | $238,097,000 | $289,438,000 | $288,242,000 |
| Operating Expense | $3,246,668,000 | $2,896,607,000 | $2,801,047,000 | $2,606,589,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-356,148,000 | $560,120,000 | $414,832,000 | $-224,060,000 |
| Net Interest Income | $-195,051,000 | $-238,097,000 | $-289,438,000 | $-288,242,000 |
| Normalized Income | $394,691,700 | $574,483,780 | $422,900,270 | $247,419,900 |
| Net Income From Continuing And Discontinued Operation | $-356,148,000 | $560,120,000 | $414,832,000 | $-224,060,000 |
| Total Operating Income As Reported | $-430,240,000 | $716,630,000 | $578,580,000 | $-65,528,000 |
| Average Dilution Earnings | $0 | $10,762,000 | $24,876,000 | $0 |
| Net Income Common Stockholders | $-356,148,000 | $560,120,000 | $414,832,000 | $-224,060,000 |
| Net Income | $-356,148,000 | $560,120,000 | $414,832,000 | $-224,060,000 |
| Net Income Including Noncontrolling Interests | $-356,148,000 | $560,120,000 | $414,832,000 | $-224,060,000 |
| Net Income Continuous Operations | $-356,148,000 | $560,120,000 | $414,832,000 | $-224,060,000 |
| Earnings From Equity Interest Net Of Tax | $-732,000 | $-1,660,000 | $-3,009,000 | $-9,921,000 |
| Pretax Income | $-627,859,000 | $470,351,000 | $297,929,000 | $-372,784,000 |
| Special Income Charges | $-947,862,000 | $-10,000,000 | $-19,000,000 | $-577,796,000 |
| Operating Income | $517,622,000 | $726,630,000 | $597,580,000 | $512,268,000 |
| Depreciation Amortization Depletion Income Statement | $654,661,000 | $627,313,000 | $608,284,000 | $599,169,000 |
| Depreciation And Amortization In Income Statement | $654,661,000 | $627,313,000 | $608,284,000 | $599,169,000 |
| Amortization Of Intangibles Income Statement | $654,661,000 | $627,313,000 | $608,284,000 | $599,169,000 |
| Gross Profit | $3,764,290,000 | $3,623,237,000 | $3,398,627,000 | $3,118,857,000 |
| Per Share | ||||
| Diluted EPS | $-5.84 | $8.65 | $6.10 | $-3.58 |
| Basic EPS | $-5.84 | $9.06 | $6.55 | $-3.58 |
| Other | ||||
| Tax Effect Of Unusual Items | $-199,590,300 | $-3,818,220 | $-2,144,730 | $-125,330,100 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $1,213,919,000 | $1,386,697,000 | $1,236,276,000 | $1,141,739,000 |
| Total Unusual Items | $-950,430,000 | $-18,182,000 | $-10,213,000 | $-596,810,000 |
| Total Unusual Items Excluding Goodwill | $-950,430,000 | $-18,182,000 | $-10,213,000 | $-596,810,000 |
| Reconciled Depreciation | $696,297,000 | $660,067,000 | $638,696,000 | $629,471,000 |
| EBITDA (Bullshit earnings) | $263,489,000 | $1,368,515,000 | $1,226,063,000 | $544,929,000 |
| EBIT | $-432,808,000 | $708,448,000 | $587,367,000 | $-84,542,000 |
| Diluted Average Shares | $60,981,000 | $66,007,000 | $72,066,000 | $62,539,000 |
| Basic Average Shares | $60,981,000 | $61,838,000 | $63,291,000 | $62,539,000 |
| Diluted NI Availto Com Stockholders | $-356,148,000 | $570,882,000 | $439,708,000 | $-224,060,000 |
| Tax Provision | $-272,443,000 | $-91,429,000 | $-119,912,000 | $-158,645,000 |
| Other Special Charges | $947,862,000 | $10,000,000 | $19,000,000 | $444,148,000 |
| Gain On Sale Of Security | $-2,568,000 | $-8,182,000 | $8,787,000 | $-19,014,000 |
| Amortization | $654,661,000 | $627,313,000 | $608,284,000 | $599,169,000 |
| Research And Development | $782,736,000 | $884,000,000 | $849,658,000 | $590,453,000 |
| Selling General And Administration | $1,809,271,000 | $1,385,294,000 | $1,343,105,000 | $1,416,967,000 |
| Impairment Of Capital Assets | - | $0 | $0 | $133,648,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,940,266,000 | $-2,378,262,000 | $-3,434,172,000 | $-4,401,365,000 |
| Total Assets | $11,659,340,000 | $12,012,257,000 | $11,393,359,000 | $10,835,255,000 |
| Total Non Current Assets | $7,493,297,000 | $7,383,229,000 | $7,957,931,000 | $8,229,115,000 |
| Other Non Current Assets | $99,030,000 | $114,482,000 | $67,464,000 | $55,139,000 |
| Non Current Deferred Assets | $876,680,000 | $569,734,000 | $484,312,000 | $385,501,000 |
| Non Current Deferred Taxes Assets | $869,130,000 | $560,245,000 | $477,834,000 | $376,247,000 |
| Goodwill And Other Intangible Assets | $6,258,850,000 | $6,472,018,000 | $7,171,169,000 | $7,487,099,000 |
| Other Intangible Assets | $4,429,510,000 | $4,755,695,000 | $5,418,039,000 | $5,794,437,000 |
| Current Assets | $4,166,043,000 | $4,629,028,000 | $3,435,428,000 | $2,606,140,000 |
| Other Current Assets | $323,954,000 | $261,543,000 | $320,809,000 | $91,135,000 |
| Prepaid Assets | $152,481,000 | $177,411,000 | $185,476,000 | $91,912,000 |
| Inventory | $416,962,000 | $480,445,000 | $597,039,000 | $714,061,000 |
| Receivables | $830,747,000 | $716,765,000 | $705,794,000 | $651,493,000 |
| Accounts Receivable | $830,747,000 | $716,765,000 | $705,794,000 | $651,493,000 |
| Allowance For Doubtful Accounts Receivable | $-17,294,000 | $-32,691,000 | $-21,136,000 | $-17,843,000 |
| Gross Accounts Receivable | $848,041,000 | $749,456,000 | $726,930,000 | $669,336,000 |
| Cash Cash Equivalents And Short Term Investments | $2,441,899,000 | $2,992,864,000 | $1,626,310,000 | $881,482,000 |
| Cash And Cash Equivalents | $1,391,899,000 | $2,412,864,000 | $1,506,310,000 | $881,482,000 |
| Cash Equivalents | $709,153,000 | $1,463,970,000 | $1,068,586,000 | $547,464,000 |
| Cash Financial | $682,746,000 | $948,894,000 | $437,724,000 | $334,018,000 |
| Current Deferred Assets | - | - | $171,507,000 | $176,057,000 |
| Debt | ||||
| Net Debt | $3,966,358,000 | $3,695,776,000 | $4,206,632,000 | $4,842,859,000 |
| Total Debt | $5,423,866,000 | $6,162,357,000 | $5,791,614,000 | $5,812,117,000 |
| Long Term Debt And Capital Lease Obligation | $4,379,246,000 | $6,116,578,000 | $5,167,213,000 | $5,765,179,000 |
| Long Term Debt | $4,328,354,000 | $6,077,640,000 | $5,107,988,000 | $5,693,341,000 |
| Current Debt And Capital Lease Obligation | $1,044,620,000 | $45,779,000 | $624,401,000 | $46,938,000 |
| Current Debt | $1,029,903,000 | $31,000,000 | $604,954,000 | $31,000,000 |
| Other Current Borrowings | $1,029,903,000 | $31,000,000 | $604,954,000 | $31,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $7,340,756,000 | $7,918,501,000 | $7,656,362,000 | $7,749,521,000 |
| Total Non Current Liabilities Net Minority Interest | $5,098,235,000 | $6,879,928,000 | $6,119,670,000 | $6,816,328,000 |
| Other Non Current Liabilities | $124,519,000 | $86,614,000 | $104,751,000 | $106,812,000 |
| Non Current Deferred Liabilities | $594,470,000 | $676,736,000 | $847,706,000 | $944,337,000 |
| Non Current Deferred Taxes Liabilities | $594,470,000 | $676,736,000 | $847,706,000 | $944,337,000 |
| Current Liabilities | $2,242,521,000 | $1,038,573,000 | $1,536,692,000 | $933,193,000 |
| Other Current Liabilities | $4,225,000 | $10,198,000 | $681,000 | - |
| Payables And Accrued Expenses | $951,913,000 | $803,035,000 | $769,966,000 | $716,385,000 |
| Interest Payable | $40,667,000 | $41,626,000 | $36,443,000 | $35,614,000 |
| Payables | $178,448,000 | $96,626,000 | $137,824,000 | $98,475,000 |
| Total Tax Payable | $56,387,000 | $18,757,000 | $35,074,000 | $7,717,000 |
| Income Tax Payable | $56,387,000 | $18,757,000 | $35,074,000 | $7,717,000 |
| Accounts Payable | $122,061,000 | $77,869,000 | $102,750,000 | $90,758,000 |
| Current Deferred Liabilities | - | - | $0 | $463,000 |
| Equity | ||||
| Common Stock Equity | $4,318,584,000 | $4,093,756,000 | $3,736,997,000 | $3,085,734,000 |
| Total Equity Gross Minority Interest | $4,318,584,000 | $4,093,756,000 | $3,736,997,000 | $3,085,734,000 |
| Stockholders Equity | $4,318,584,000 | $4,093,756,000 | $3,736,997,000 | $3,085,734,000 |
| Gains Losses Not Affecting Retained Earnings | $-568,598,000 | $-947,667,000 | $-842,147,000 | $-1,125,509,000 |
| Other Equity Adjustments | $-568,598,000 | $-947,667,000 | $-842,147,000 | $-1,125,509,000 |
| Retained Earnings | $646,176,000 | $1,127,347,000 | $878,656,000 | $733,586,000 |
| Other | ||||
| Ordinary Shares Number | $61,435,000 | $60,631,000 | $62,255,000 | $63,214,000 |
| Share Issued | $61,435,000 | $60,631,000 | $62,255,000 | $63,214,000 |
| Tangible Book Value | $-1,940,266,000 | $-2,378,262,000 | $-3,434,172,000 | $-4,401,365,000 |
| Invested Capital | $9,676,841,000 | $10,202,396,000 | $9,449,939,000 | $8,810,075,000 |
| Working Capital | $1,923,522,000 | $3,590,455,000 | $1,898,736,000 | $1,672,947,000 |
| Capital Lease Obligations | $65,609,000 | $53,717,000 | $78,672,000 | $87,776,000 |
| Total Capitalization | $8,646,938,000 | $10,171,396,000 | $8,844,985,000 | $8,779,075,000 |
| Additional Paid In Capital | $4,240,945,000 | $3,914,015,000 | $3,700,427,000 | $3,477,596,000 |
| Capital Stock | $61,000 | $61,000 | $61,000 | $61,000 |
| Common Stock | $61,000 | $61,000 | $61,000 | $61,000 |
| Long Term Capital Lease Obligation | $50,892,000 | $38,938,000 | $59,225,000 | $71,838,000 |
| Current Capital Lease Obligation | $14,717,000 | $14,779,000 | $19,447,000 | $15,938,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $215,351,000 | $153,133,000 | $121,209,000 | $143,243,000 |
| Current Provisions | $26,412,000 | $26,428,000 | $20,435,000 | $26,164,000 |
| Current Accrued Expenses | $773,465,000 | $706,409,000 | $632,142,000 | $617,910,000 |
| Goodwill | $1,829,340,000 | $1,716,323,000 | $1,753,130,000 | $1,692,662,000 |
| Net PPE | $258,737,000 | $226,995,000 | $234,986,000 | $301,376,000 |
| Accumulated Depreciation | $-178,553,000 | $-161,957,000 | $-133,351,000 | $-107,647,000 |
| Gross PPE | $437,290,000 | $388,952,000 | $368,337,000 | $409,023,000 |
| Leases | $63,569,000 | $70,201,000 | $67,722,000 | $64,776,000 |
| Construction In Progress | $49,635,000 | $34,493,000 | $18,661,000 | $67,385,000 |
| Other Properties | $58,880,000 | $53,582,000 | $65,340,000 | $73,326,000 |
| Machinery Furniture Equipment | $192,976,000 | $158,774,000 | $145,702,000 | $134,601,000 |
| Land And Improvements | $72,230,000 | $71,902,000 | $70,912,000 | $68,935,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $141,649,000 | $148,532,000 | $139,712,000 | $175,605,000 |
| Work In Process | $253,350,000 | $311,752,000 | $431,732,000 | $517,670,000 |
| Raw Materials | $21,963,000 | $20,161,000 | $25,595,000 | $20,786,000 |
| Other Short Term Investments | $1,050,000,000 | $580,000,000 | $120,000,000 | $0 |
| Current Deferred Revenue | - | - | $0 | $463,000 |
| Non Current Deferred Revenue | - | - | - | $0 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $1,146,021,000 | $1,347,838,000 | $1,049,045,000 | $773,783,000 |
| Operating Activities | ||||
| Operating Cash Flow | $1,355,773,000 | $1,395,908,000 | $1,092,007,000 | $1,271,977,000 |
| Cash Flow From Continuing Operating Activities | $1,355,773,000 | $1,395,908,000 | $1,092,007,000 | $1,271,977,000 |
| Operating Gains Losses | - | - | - | $37,704,000 |
| Investing Activities | ||||
| Capital Expenditure | $-209,752,000 | $-48,070,000 | $-42,962,000 | $-498,194,000 |
| Investing Cash Flow | $-1,509,913,000 | $-508,195,000 | $-163,062,000 | $-446,230,000 |
| Cash Flow From Continuing Investing Activities | $-1,509,913,000 | $-508,195,000 | $-163,062,000 | $-446,230,000 |
| Net Other Investing Changes | $28,167,000 | - | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-125,023,000 | $-311,429,000 | $-269,761,000 | $-54,000 |
| Financing Cash Flow | $-873,380,000 | $20,516,000 | $-305,254,000 | $-529,491,000 |
| Cash Flow From Continuing Financing Activities | $-873,380,000 | $20,516,000 | $-305,254,000 | $-529,491,000 |
| Net Other Financing Charges | $-75,220,000 | $-63,469,000 | $-50,952,000 | $-45,443,000 |
| Net Common Stock Issuance | $-125,023,000 | $-311,429,000 | $-269,761,000 | $-54,000 |
| Dividend Received Cfo | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-781,000,000 | $-606,000,000 | $-31,000,000 | $-582,014,000 |
| Issuance Of Debt | $0 | $980,767,000 | $0 | $0 |
| Interest Paid Supplemental Data | $248,553,000 | $314,822,000 | $333,112,000 | $270,671,000 |
| Income Tax Paid Supplemental Data | $121,808,000 | $114,907,000 | $177,880,000 | $94,681,000 |
| End Cash Position | $1,391,899,000 | $2,412,864,000 | $1,506,310,000 | $881,482,000 |
| Beginning Cash Position | $2,412,864,000 | $1,506,310,000 | $881,482,000 | $591,448,000 |
| Effect Of Exchange Rate Changes | $6,555,000 | $-1,675,000 | $1,137,000 | $-6,222,000 |
| Changes In Cash | $-1,027,520,000 | $908,229,000 | $623,691,000 | $296,256,000 |
| Proceeds From Stock Option Exercised | $107,863,000 | $20,647,000 | $46,459,000 | $98,020,000 |
| Common Stock Payments | $-125,023,000 | $-311,429,000 | $-269,761,000 | $-54,000 |
| Net Issuance Payments Of Debt | $-781,000,000 | $374,767,000 | $-31,000,000 | $-582,014,000 |
| Net Long Term Debt Issuance | $-781,000,000 | $374,767,000 | $-31,000,000 | $-582,014,000 |
| Long Term Debt Payments | $-781,000,000 | $-606,000,000 | $-31,000,000 | $-582,014,000 |
| Long Term Debt Issuance | $0 | $980,767,000 | $0 | $0 |
| Net Investment Purchase And Sale | $-470,275,000 | $-460,125,000 | $-120,100,000 | $-1,036,000 |
| Sale Of Investment | $1,360,000,000 | $845,000,000 | $270,000,000 | $60,000,000 |
| Purchase Of Investment | $-1,830,275,000 | $-1,305,125,000 | $-390,100,000 | $-61,036,000 |
| Net Business Purchase And Sale | $-858,053,000 | $0 | $0 | $53,000,000 |
| Purchase Of Business | $-858,053,000 | $0 | $0 | $0 |
| Net Intangibles Purchase And Sale | $-151,000,000 | $-10,000,000 | $-19,000,000 | $-469,148,000 |
| Purchase Of Intangibles | $-151,000,000 | $-10,000,000 | $-19,000,000 | $-469,148,000 |
| Net PPE Purchase And Sale | $-58,752,000 | $-38,070,000 | $-23,962,000 | $-29,046,000 |
| Purchase Of PPE | $-58,752,000 | $-38,070,000 | $-23,962,000 | $-29,046,000 |
| Change In Working Capital | $18,899,000 | $-76,720,000 | $-204,439,000 | $9,905,000 |
| Change In Other Current Liabilities | $28,018,000 | $-39,272,000 | $-23,599,000 | $-27,818,000 |
| Change In Payables And Accrued Expense | $154,171,000 | $51,344,000 | $11,578,000 | $153,074,000 |
| Change In Accrued Expense | $77,096,000 | $86,159,000 | $-23,245,000 | $165,991,000 |
| Change In Payable | $77,075,000 | $-34,815,000 | $34,823,000 | $-12,917,000 |
| Change In Account Payable | $39,851,000 | $-20,073,000 | $9,603,000 | $-11,225,000 |
| Change In Tax Payable | $37,224,000 | $-14,742,000 | $25,220,000 | $-1,692,000 |
| Change In Income Tax Payable | $37,224,000 | $-14,742,000 | $25,220,000 | $-1,692,000 |
| Change In Prepaid Assets | $29,030,000 | $-22,135,000 | $-127,115,000 | $35,788,000 |
| Change In Inventory | $-86,041,000 | $-45,542,000 | $-13,420,000 | $-49,642,000 |
| Change In Receivables | $-106,279,000 | $-21,115,000 | $-51,883,000 | $-90,135,000 |
| Changes In Account Receivables | $-106,279,000 | $-21,115,000 | $-51,883,000 | $-90,135,000 |
| Other Non Cash Items | $1,131,455,000 | $184,965,000 | $204,167,000 | $741,027,000 |
| Stock Based Compensation | $291,133,000 | $248,045,000 | $226,841,000 | $221,996,000 |
| Provisionand Write Offof Assets | $19,108,000 | $27,758,000 | $11,113,000 | $14,537,000 |
| Asset Impairment Charge | $0 | $0 | $61,014,000 | $133,648,000 |
| Deferred Tax | $-444,971,000 | $-208,327,000 | $-260,217,000 | $-292,251,000 |
| Deferred Income Tax | $-444,971,000 | $-208,327,000 | $-260,217,000 | $-292,251,000 |
| Depreciation Amortization Depletion | $696,297,000 | $660,067,000 | $638,696,000 | $629,471,000 |
| Depreciation And Amortization | $696,297,000 | $660,067,000 | $638,696,000 | $629,471,000 |
| Amortization Cash Flow | $654,661,000 | $627,313,000 | $608,284,000 | $599,169,000 |
| Amortization Of Intangibles | $654,661,000 | $627,313,000 | $608,284,000 | $599,169,000 |
| Depreciation | $41,636,000 | $32,754,000 | $30,412,000 | $30,302,000 |
| Net Income From Continuing Operations | $-356,148,000 | $560,120,000 | $414,832,000 | $-224,060,000 |
| Sale Of Business | - | $0 | $0 | $53,000,000 |
| Change In Other Current Assets | - | $-32,709,000 | $-936,000 | $-9,269,000 |
| Gain Loss On Sale Of Business | - | $0 | $0 | $37,704,000 |
| Change In Other Working Capital | - | - | $-463,000 | $-2,093,000 |
| Net Short Term Debt Issuance | - | - | - | $0 |
| Short Term Debt Payments | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-06-23